Recent Acquisition The acquisition of Cerus Endovascular by Stryker enhances its market reach and resources, indicating a growing interest from major players in neurointerventional technologies and creating opportunities for partnerships or supply agreements.

Innovative Product Launch Cerus developed and received FDA clearance for 027 microcatheters, demonstrating ongoing innovation and potential demand for neurovascular devices, especially as neurointerventional procedures continue to expand.

Funding & Growth With recent Series B financing of $19 million, Cerus Endovascular shows strong investor confidence, enabling expansion of its product development and sales efforts in the competitive neurovascular device market.

Market Focus Specializing in minimally invasive devices for intracranial aneurysm treatment, Cerus offers targeted solutions that can be integrated into hospitals and vascular centers seeking cutting-edge neurointerventional options.

Strategic Partnerships The company's focus on proprietary and differentiated devices positions it as a valuable partner for medtech suppliers and distributors seeking innovative neurovascular solutions to expand their product portfolio.